CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?
Publication type: Journal Article
Publication date: 2020-09-02
scimago Q2
wos Q3
SJR: 0.756
CiteScore: 5.1
Impact factor: 2.3
ISSN: 00912700, 15524604
PubMed ID:
32875599
Pharmacology
Pharmacology (medical)
Abstract
CD33 is a transmembrane protein that is found on cells of myeloid lineage. It is also intensely expressed on acute myeloid leukemia (AML) progenitor cells but not on normal stem cells. It internalizes on binding and dimerization, making it a specific and ideal target for AML therapeutics and drug delivery. Several targeted therapies have been tested and many are still currently in development. Gemtuzumab ozogamicin was the first and only CD33-directed antibody-drug conjugate to be US Food and Drug Administration approved for AML. Other targeted agents have not achieved such success. Promising new strategies include cellular therapy mechanisms and linker molecules. This is an exciting target that requires a considerable amount of precision to yield clinical benefit.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Cancers
2 publications, 8.33%
|
|
|
Frontiers in Immunology
2 publications, 8.33%
|
|
|
Oncotarget
1 publication, 4.17%
|
|
|
International Journal of Molecular Sciences
1 publication, 4.17%
|
|
|
Biophysical Reviews
1 publication, 4.17%
|
|
|
Biomarker Research
1 publication, 4.17%
|
|
|
Coordination Chemistry Reviews
1 publication, 4.17%
|
|
|
Leukemia Research Reports
1 publication, 4.17%
|
|
|
Fundamental and Clinical Pharmacology
1 publication, 4.17%
|
|
|
Haematologica
1 publication, 4.17%
|
|
|
Blood
1 publication, 4.17%
|
|
|
Seminars in Immunology
1 publication, 4.17%
|
|
|
bioRxiv
1 publication, 4.17%
|
|
|
Heliyon
1 publication, 4.17%
|
|
|
Modern Pathology
1 publication, 4.17%
|
|
|
Molecular Cancer Therapeutics
1 publication, 4.17%
|
|
|
Journal of Cellular and Molecular Medicine
1 publication, 4.17%
|
|
|
Frontiers in Endocrinology
1 publication, 4.17%
|
|
|
Journal of Molecular Structure
1 publication, 4.17%
|
|
|
Russian Chemical Reviews
1 publication, 4.17%
|
|
|
Interdisciplinary Cancer Research
1 publication, 4.17%
|
|
|
Blood Cancer Journal
1 publication, 4.17%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
|
|
|
Elsevier
6 publications, 25%
|
|
|
Springer Nature
4 publications, 16.67%
|
|
|
MDPI
3 publications, 12.5%
|
|
|
Frontiers Media S.A.
3 publications, 12.5%
|
|
|
Wiley
2 publications, 8.33%
|
|
|
Impact Journals
1 publication, 4.17%
|
|
|
Ferrata Storti Foundation
1 publication, 4.17%
|
|
|
American Society of Hematology
1 publication, 4.17%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 4.17%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 4.17%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 4.17%
|
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
24
Total citations:
24
Citations from 2024:
10
(41.67%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Maakaron J. et al. CD33‐Targeted Therapies: Beating the Disease or Beaten to Death? // Journal of Clinical Pharmacology. 2020. Vol. 61. No. 1. pp. 7-17.
GOST all authors (up to 50)
Copy
Maakaron J., Rogosheske J., Long M., Bachanova V., Mims A. CD33‐Targeted Therapies: Beating the Disease or Beaten to Death? // Journal of Clinical Pharmacology. 2020. Vol. 61. No. 1. pp. 7-17.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1002/jcph.1730
UR - https://doi.org/10.1002/jcph.1730
TI - CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?
T2 - Journal of Clinical Pharmacology
AU - Maakaron, Joseph
AU - Rogosheske, John
AU - Long, Meixiao
AU - Bachanova, Veronika
AU - Mims, Alice
PY - 2020
DA - 2020/09/02
PB - Wiley
SP - 7-17
IS - 1
VL - 61
PMID - 32875599
SN - 0091-2700
SN - 1552-4604
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2020_Maakaron,
author = {Joseph Maakaron and John Rogosheske and Meixiao Long and Veronika Bachanova and Alice Mims},
title = {CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?},
journal = {Journal of Clinical Pharmacology},
year = {2020},
volume = {61},
publisher = {Wiley},
month = {sep},
url = {https://doi.org/10.1002/jcph.1730},
number = {1},
pages = {7--17},
doi = {10.1002/jcph.1730}
}
Cite this
MLA
Copy
Maakaron, Joseph, et al. “CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?.” Journal of Clinical Pharmacology, vol. 61, no. 1, Sep. 2020, pp. 7-17. https://doi.org/10.1002/jcph.1730.